NPIL Pharma to acquire Pfizer's UK facility
Nicholas Piramal India Ltd on Thursday said its UK subsidiary has entered into an agreement to acquire the manufacturing facility of global pharma company Pfizer Inc at Morpeth, UK, on an asset purchase basis.
By PTI |
MUMBAI: Nicholas Piramal India Ltd on Thursday said its UK subsidiary has entered into an agreement to acquire the manufacturing facility of global pharma company Pfizer Inc at Morpeth, UK, on an asset purchase basis.
The deal includes a supply agreement till November 2011, totalling potential revenues of above $350 million, site fixed assets and property and certain net current assets, Nicholas Piramal informed the Bombay Stock Exchange.
The transaction is on a liability and cash free basis and completion is subject to required regulatory and other approvals, expected by June 19. However, the company did not disclose the financial details of the agreement.
The Morpeth unit is one of Pfizer's global, integrated facilities with end-to-end production and supply chain capabilities that cover Active Pharmaceutical Ingredients, finished dosage, packaging and distribution, it said.
The purchase by the company's subsidiary, NPIL Pharmaceuticals, would expand its global footprint, particularly in the finished Active Pharmaceutical Ingredient, contained finished dosage, packaging and supply chain areas, it added.
The company expects significant synergies of its current operations and business pipeline with Morpeth.
The acquisition is the third by Nicholas Piramal after the acquisition of Rhodia's inhalation anaesthetics business in December 2004 and acquisition of Avecia's custom manufacturing business in December 2005.
The deal includes a supply agreement till November 2011, totalling potential revenues of above $350 million, site fixed assets and property and certain net current assets, Nicholas Piramal informed the Bombay Stock Exchange.
The transaction is on a liability and cash free basis and completion is subject to required regulatory and other approvals, expected by June 19. However, the company did not disclose the financial details of the agreement.
The Morpeth unit is one of Pfizer's global, integrated facilities with end-to-end production and supply chain capabilities that cover Active Pharmaceutical Ingredients, finished dosage, packaging and distribution, it said.
The purchase by the company's subsidiary, NPIL Pharmaceuticals, would expand its global footprint, particularly in the finished Active Pharmaceutical Ingredient, contained finished dosage, packaging and supply chain areas, it added.
The company expects significant synergies of its current operations and business pipeline with Morpeth.
ADVERTISEMENT
The acquisition is the third by Nicholas Piramal after the acquisition of Rhodia's inhalation anaesthetics business in December 2004 and acquisition of Avecia's custom manufacturing business in December 2005.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
